Ashley Pinckney1, Mark R Rigby2, Lynette Keyes-Elstein1, Carol L Soppe3, Gerald T Nepom4, Mario R Ehlers5. 1. Federal Systems Division, Rho Inc, Chapel Hill, North Carolina. 2. Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana. 3. Clinical Trials Group, Immune Tolerance Network, San Francisco, California. 4. Benaroya Research Institute at Virginia Mason, Seattle, Washington. 5. Clinical Trials Group, Immune Tolerance Network, San Francisco, California. Electronic address: mehlers@immunetolerance.org.
Abstract
PURPOSE: In natural history studies, maintenance of higher levels of C-peptide secretion (a measure of endogenous insulin production) correlates with a lower incidence of major hypoglycemic events in patients with type 1 diabetes mellitus (T1D), but it is unclear whether this is also true for drug-induced C-peptide preservation. METHODS: We analyzed hypoglycemic events and glycemic control data from the T1DAL (Inducing Remission in New-Onset T1D with Alefacept) study, a trial of alefacept in new-onset T1D, which found significant C-peptide preservation at 1 and 2 years. We performed a post hoc analysis using mixed models of the association between the meal-stimulated 4-hour C-peptide AUC (4-hour AUC) and rates of major hypoglycemia, measures of glycemic control (glycosylated hemoglobin [HbA1c]; mean glucometer readings), and variability (glucometer SDs; highest and lowest readings), and an index of partial remission (insulin dose-adjusted HbA1c[ IDAA1c]). FINDINGS: Data from 49 participants (33 in the alefacept group and 16 in theplacebo group) were analyzed at baseline and 12 and 24 months. We found that the 4-hour AUC at baseline and at 1 year was a significant predictor of the number of hypoglycemic events during the ensuing 12-month interval (p = 0.030). There was a strong association between the 4-hour AUC and glucometer SDs (P < 0.001), highest readings (p < 0.001), and lowest readings (p = 0.03), all measures of glycemic variability. There was a strong inverse correlation between the 4-hour AUC and 2 measures of glycemic control: HbA1c and mean glucometer readings (both p < 0.001). There was also a strong inverse correlation between the 4-hour AUC and IDAA1c values (p < 0.001), as well as a strong correlation between IDAA1c values and glucometer SDs (p < 0.001), suggesting that reduced glycemic variability is associated with a trend toward partial remission. None of these analyses found a significant difference between the alefacept and placebo groups. IMPLICATIONS: Measures of glycemic variability and control, including rates of hypoglycemia, are significantly correlated with preservation of C-peptide regardless of whether this is achieved by immune intervention with alefacept or natural variability in patients with new-onset T1D. Thus, preservation of endogenous insulin production by an immunomodulatory drug may confer clinical benefits similar to those seen in patients with higher C-peptide secretion due to slow disease progression.
RCT Entities:
PURPOSE: In natural history studies, maintenance of higher levels of C-peptide secretion (a measure of endogenous insulin production) correlates with a lower incidence of major hypoglycemic events in patients with type 1 diabetes mellitus (T1D), but it is unclear whether this is also true for drug-induced C-peptide preservation. METHODS: We analyzed hypoglycemic events and glycemic control data from the T1DAL (Inducing Remission in New-Onset T1D with Alefacept) study, a trial of alefacept in new-onset T1D, which found significant C-peptide preservation at 1 and 2 years. We performed a post hoc analysis using mixed models of the association between the meal-stimulated 4-hour C-peptide AUC (4-hour AUC) and rates of major hypoglycemia, measures of glycemic control (glycosylated hemoglobin [HbA1c]; mean glucometer readings), and variability (glucometer SDs; highest and lowest readings), and an index of partial remission (insulin dose-adjusted HbA1c[ IDAA1c]). FINDINGS: Data from 49 participants (33 in the alefacept group and 16 in the placebo group) were analyzed at baseline and 12 and 24 months. We found that the 4-hour AUC at baseline and at 1 year was a significant predictor of the number of hypoglycemic events during the ensuing 12-month interval (p = 0.030). There was a strong association between the 4-hour AUC and glucometer SDs (P < 0.001), highest readings (p < 0.001), and lowest readings (p = 0.03), all measures of glycemic variability. There was a strong inverse correlation between the 4-hour AUC and 2 measures of glycemic control: HbA1c and mean glucometer readings (both p < 0.001). There was also a strong inverse correlation between the 4-hour AUC and IDAA1c values (p < 0.001), as well as a strong correlation between IDAA1c values and glucometer SDs (p < 0.001), suggesting that reduced glycemic variability is associated with a trend toward partial remission. None of these analyses found a significant difference between the alefacept and placebo groups. IMPLICATIONS: Measures of glycemic variability and control, including rates of hypoglycemia, are significantly correlated with preservation of C-peptide regardless of whether this is achieved by immune intervention with alefacept or natural variability in patients with new-onset T1D. Thus, preservation of endogenous insulin production by an immunomodulatory drug may confer clinical benefits similar to those seen in patients with higher C-peptide secretion due to slow disease progression.
Authors: Maria Koulmanda; Manoj Bhasin; Zuheir Awdeh; Andi Qipo; Zhigang Fan; Dusan Hanidziar; Prabhakar Putheti; Hang Shi; Eva Csizuadia; Towia A Libermann; Terry B Strom Journal: PLoS One Date: 2012-05-11 Impact factor: 3.240
Authors: Nelly Mauras; Paul Mazaika; Bruce Buckingham; Stuart Weinzimer; Neil H White; Eva Tsalikian; Tamara Hershey; Allison Cato; Peiyao Cheng; Craig Kollman; Roy W Beck; Katrina Ruedy; Tandy Aye; Larry Fox; Ana Maria Arbelaez; Darrell Wilson; Michael Tansey; William Tamborlane; Daniel Peng; Matthew Marzelli; Karen K Winer; Allan L Reiss Journal: Diabetes Date: 2014-12-08 Impact factor: 9.461
Authors: Vladimir Kron; Miroslav Verner; Pavel Smetana; Jana Janoutova; Vladimir Janout; Karel Martinik Journal: J Appl Biomed Date: 2020-12-08 Impact factor: 1.797
Authors: S M Marren; S Hammersley; T J McDonald; B M Shields; B A Knight; A Hill; R Bolt; T I Tree; B O Roep; A T Hattersley; A G Jones; R A Oram Journal: Diabet Med Date: 2019-06-27 Impact factor: 4.359
Authors: Jaquellyne Gurgel Penaforte-Saboia; Carlos Eduardo Barra Couri; Virginia Oliveira Fernandes; Ana Paula Dias Rangel Montenegro; Lívia Aline De Araújo Batista; Lenita Zajdenverg; Carlos Antonio Negrato; Kelen Cristina Ribeiro Malmegrim; Daniela Aparecida Moraes; Juliana Bernardes Elias Dias; Maria Carolina Oliveira; Akhtar Hussain; Marilia Brito Gomes; Renan Magalhães Montenegro Journal: Front Endocrinol (Lausanne) Date: 2019-11-19 Impact factor: 5.555
Authors: Suzy V Hope; Bridget A Knight; Beverley M Shields; Anita V Hill; Pratik Choudhary; W David Strain; Timothy J McDonald; Angus G Jones Journal: Diabetologia Date: 2017-10-05 Impact factor: 10.122